GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Rosetta Genomics Ltd (FRA:RQ1) » Definitions » Shiller PE Ratio

Rosetta Genomics (FRA:RQ1) Shiller PE Ratio : (As of Jun. 23, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Rosetta Genomics Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Rosetta Genomics Shiller PE Ratio Historical Data

The historical data trend for Rosetta Genomics's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rosetta Genomics Shiller PE Ratio Chart

Rosetta Genomics Annual Data
Trend Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Rosetta Genomics Quarterly Data
Dec10 Mar11 Jun11 Dec11 Jun12 Dec12 Jun13 Dec13 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Jun17
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Rosetta Genomics's Shiller PE Ratio

For the Diagnostics & Research subindustry, Rosetta Genomics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rosetta Genomics's Shiller PE Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Rosetta Genomics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Rosetta Genomics's Shiller PE Ratio falls into.



Rosetta Genomics Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Rosetta Genomics's E10 for the quarter that ended in Jun. 2017 is calculated as:

For example, Rosetta Genomics's adjusted earnings per share data for the three months ended in Jun. 2017 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Jun. 2017 (Change)*Current CPI (Jun. 2017)
=-0.721/103.3491*103.3491
=-0.721

Current CPI (Jun. 2017) = 103.3491.

Rosetta Genomics Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
200512 -443.080 83.032 -551.497
200603 -430.790 84.298 -528.149
200606 -409.535 85.606 -494.419
200609 -407.462 85.606 -491.916
200612 -446.932 85.142 -542.508
200703 -125.028 86.640 -149.140
200706 -101.916 87.906 -119.820
200709 -93.182 87.964 -109.479
200712 -361.087 88.616 -421.119
200803 -153.014 90.090 -175.535
200806 -143.518 92.320 -160.663
200809 -120.442 92.307 -134.850
200812 47.952 88.697 55.873
200903 -165.456 89.744 -190.539
200906 -205.632 91.003 -233.529
200909 -118.541 91.120 -134.451
200912 -138.298 91.111 -156.874
201003 -122.047 91.821 -137.370
201006 -159.019 91.962 -178.710
201009 -109.872 92.162 -123.209
201012 -115.670 92.474 -129.273
201103 -35.935 94.283 -39.390
201106 -42.390 95.235 -46.002
201112 -13.224 95.213 -14.354
201206 -51.171 96.819 -54.622
201212 -0.385 96.871 -0.411
201306 -0.515 98.518 -0.540
201312 -0.483 98.326 -0.508
201406 -4.460 100.560 -4.584
201409 -2.700 100.428 -2.779
201412 -3.333 99.070 -3.477
201503 -3.326 99.621 -3.450
201506 -2.138 100.684 -2.195
201509 -2.887 100.392 -2.972
201512 -4.287 99.792 -4.440
201603 -2.155 100.470 -2.217
201606 -1.736 101.688 -1.764
201609 -2.031 101.861 -2.061
201612 -2.569 101.863 -2.606
201706 -0.721 103.349 -0.721

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Rosetta Genomics  (FRA:RQ1) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Rosetta Genomics Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Rosetta Genomics's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Rosetta Genomics (FRA:RQ1) Business Description

Traded in Other Exchanges
N/A
Address
10 Plaut Street, Science Park, Rehovot, ISR, 76706
Rosetta Genomics Ltd is an Israel based genomic diagnostics company operating globally. It is focused on research and development on diagnostics and therapeutics in the field of microRNAs. The firm markets and sells four diagnostic tests based on its microRNA technologies namely, RosettaGX Cancer Origin for the identification of the primary site of metastatic cancer, mi-LUNG, mi-KIDNEY which is a microRNA-based kidney tumor classification test for pathology samples and RosettaGx Reveal which is a microRNA-based assay for the diagnosis of indeterminate thyroid fine-needle aspirate samples. Its revenues include Clinical testing revenues and Licensing revenues, of which Clinical testing revenue is maximum. The group generates its revenues mainly from diagnosing patient tissue.

Rosetta Genomics (FRA:RQ1) Headlines

No Headlines